Related Experiment Video
Updated: Jun 28, 2025

Echocardiographic Assessment Using Subxiphoid-Only Examination for Hypotensive Patients
Published on: April 18, 2025
Protocol for a Randomized Controlled Trial to Evaluate a Permissive Blood Pressure Target Versus Usual Care in
Robert Darnell1, Alanna Brown1, Emma Laing1
1Clinical Trials Unit, Intensive Care National Audit and Research Centre (ICNARC), London, United Kingdom.
Insights
The PRESSURE trial investigates if a permissive mean arterial pressure (MAP) target improves outcomes for hypotensive children in pediatric intensive care units (PICUs). This study compares a lower MAP target to usual care to determine clinical and cost-effectiveness.
Area of Science:
- Pediatric Critical Care Medicine
- Pediatric Cardiology
- Clinical Trial Design
Background:
- Hypotension management is crucial in pediatric critical care.
- Current optimal blood pressure targets for hypotensive children are not well-defined.
- Vasoactive drugs and fluids are standard treatments for pediatric hypotension.
Purpose of the Study:
- To evaluate the clinical and cost-effectiveness of a permissive mean arterial pressure (MAP) target in pediatric patients.
- To compare a permissive MAP target (greater than the fifth centile for age) against usual care in hypotensive children.
- To assess the impact of different blood pressure management strategies on patient outcomes.
Main Methods:
- A pragmatic, open-label, multicenter, parallel-group randomized control trial (RCT) with an integrated economic evaluation.
- The study includes infants and children aged 37 weeks corrected gestational age to 16 years admitted to 18 UK PICUs, on mechanical ventilation and receiving vasoactive drugs.
- Intervention involves adjusting hemodynamic support to achieve a permissive MAP target greater than the fifth centile for age.
Main Results:
- The primary outcome is a composite of death and days of ventilatory support within 30 days.
- Patients are randomized 1:1 to either a permissive MAP target or usual care.
- Data collected include baseline demographics, clinical status, daily blood pressure, organ support measures, and discharge outcomes.
Conclusions:
- The findings of the PRESSURE trial will provide evidence on the optimal blood pressure management in critically ill children.
- Dissemination of results is planned through national and international conferences and peer-reviewed publications.
- The study aims to inform clinical practice guidelines for pediatric hypotension management.
Objectives:
Management of hypotension is a fundamental part of pediatric critical care, with cardiovascular support in the form of fluids or vasoactive drugs offered to every hypotensive child. However, optimal blood pressure (BP) targets are unknown. The PRotocolised Evaluation of PermiSSive BP Targets Versus Usual CaRE (PRESSURE) trial aims to evaluate the clinical and cost-effectiveness of a permissive mean arterial pressure (MAP) target of greater than a fifth centile for age compared with usual care.
Design:
Pragmatic, open, multicenter, parallel-group randomized control trial (RCT) with integrated economic evaluation.
Setting:
Eighteen PICUs across the United Kingdom.
Patients:
Infants and children older than 37 weeks corrected gestational age to 16 years accepted to a participating PICU, on mechanical ventilation and receiving vasoactive drugs for hypotension.
Interventions:
Adjustment of hemodynamic support to achieve a permissive MAP target greater than fifth centile for age during invasive mechanical ventilation.
Measurements And Main Results:
Randomization is 1:1 to a permissive MAP target or usual care, stratified by site and age group. Due to the emergency nature of the treatment, approaching patients for written informed consent will be deferred until after randomization. The primary clinical outcome is a composite of death and days of ventilatory support at 30 days. Baseline demographics and clinical status will be recorded as well as daily measures of BP and organ support, and discharge outcomes. This RCT received Health Research Authority approval (reference 289545), and a favorable ethical opinion from the East of England-Cambridge South Research Ethics Committee on May 10, 2021 (reference number 21/EE/0084). The trial is registered and has an International Standard RCT Number (reference 20609635).
Conclusions:
Trial findings will be disseminated in U.K. national and international conferences and in peer-reviewed journals.
More Related Videos
Related Concept Videos
Pre-Procedural Guidelines for Assessing Blood Pressure
Blood Pressure Imbalances and Circulatory Shock
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
Measurement of Blood Pressure
Hypertension and Regulation of Blood Pressure

